, a startup focused on a new means of combating cancer and eye disease, has closed on $2.57 million in third-round financing.

VentureWire reported the closing Tuesday. Iconic is seeking to raise $4.2 million.

Icon is in pre-clinical development of technology discovered at Yale University that uses molecules called icon to kill tumors. The icon molecules kill tumors by destroying the blood vessels that feed them.

The company also is combating wet macular degeneration, an eye disease that destroys the vision in older Americans. There are two forms of macular degeneration that destroys the retina – wet, which affects about 10 percent of victims, and dry.

Icon licensed the technology from Yale.